Japanese regulators are set to approve Moderna Inc’s (MRNA.O) COVID-19 vaccine as soon as May 21, the Yomiuri Shimbun newspaper reported Saturday, without citing the source of the information.
Takeda Pharmaceutical Co (4502.T), Japan’s biggest drugmaker, is handling domestic regulatory filing and imports of about 50 million doses of the Moderna shot, or enough for 25 million people. The first doses were flown into Japan from Europe on April 30, ahead of their official approval. read more
Moderna’s would be the second such vaccine to be approved for use in Japan, after the government kicked off its inoculation campaign in the middle of February using Pfiser Inc’s (PFE.N) shot.
Progress has been slow, with less than 2 percent of Japan’s population inoculated so far, the lowest proportion among wealthy countries.
This is not a CAPTIS article. Originally, it was published here.